×
News Home

Should You Accumulate ProQR Therapeutics NV (PRQR) in Biotechnology Industry?

Tuesday, August 10, 2021 10:49 AM | InvestorsObserver Analysts
Should You Accumulate ProQR Therapeutics NV (PRQR) in Biotechnology Industry?

A rating of 81 puts ProQR Therapeutics NV (PRQR) near the top of the Biotechnology industry according to InvestorsObserver. ProQR Therapeutics NV's score of 81 means it scores higher than 81% of stocks in the industry. ProQR Therapeutics NV also received an overall rating of 50, putting it above 50% of all stocks. Biotechnology is ranked 103 out of the 148 industries.

Overall Score - 50
PRQR has an Overall Score of 50. Find out what this means to you and get the rest of the rankings on PRQR!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 50 would rank higher than 50 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With ProQR Therapeutics NV Stock Today?

ProQR Therapeutics NV (PRQR) stock has fallen -1.67% while the S&P 500 is higher by 0.01% as of 10:35 AM on Tuesday, Aug 10. PRQR has fallen -$0.11 from the previous closing price of $6.27 on volume of 480,231 shares. Over the past year the S&P 500 is up 31.91% while PRQR is higher by 13.21%. PRQR lost -$1.19 per share the over the last 12 months. Click Here to get the full Stock Report for ProQR Therapeutics NV stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App